Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
IMUX 
Immunic Inc (IMUX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/03/2025: IMUX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $10.55
1 Year Target Price $10.55
| 5 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -51.25% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 69.68M USD | Price to earnings Ratio - | 1Y Target Price 10.55 |
Price to earnings Ratio - | 1Y Target Price 10.55 | ||
Volume (30-day avg) 7 | Beta 1.49 | 52 Weeks Range 0.56 - 2.11 | Updated Date 07/4/2025 |
52 Weeks Range 0.56 - 2.11 | Updated Date 07/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.95 |
Earnings Date
Report Date 2025-06-11 | When Before Market | Estimate -0.24 | Actual -0.25 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -101.26% | Return on Equity (TTM) -246.26% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 54768522 | Price to Sales(TTM) - |
Enterprise Value 54768522 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.21 | Shares Outstanding 95817504 | Shares Floating 76268842 |
Shares Outstanding 95817504 | Shares Floating 76268842 | ||
Percent Insiders 1.35 | Percent Institutions 44.81 |
Upturn AI SWOT
Immunic Inc
Company Overview
History and Background
Immunic, Inc. is a biopharmaceutical company focused on developing orally administered, small molecule therapies that selectively target immunology pathways to treat chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohnu2019s disease, and psoriasis. Founded in 2016.
Core Business Areas
- Drug Development: Focuses on the discovery and development of novel drug candidates for autoimmune and inflammatory diseases.
Leadership and Structure
Dr. Andreas Mu00fchler is the CEO. Immunic operates with a focused management team and board of directors overseeing drug development programs and corporate strategy.
Top Products and Market Share
Key Offerings
- Vidofludimus Calcium (IMU-838): An oral selective inhibitor of DHODH (dihydroorotate dehydrogenase) being developed for relapsing-remitting multiple sclerosis (RRMS). Competitors include oral MS drugs such as Tecfidera (Biogen), Gilenya (Novartis), and Mayzent (Novartis). Market share data is not publicly available since it's not yet approved
- IMU-935: An oral selective inverse agonist of RORu03b3t being developed for psoriasis and ulcerative colitis. Competitors include biologics like Humira (AbbVie) and Stelara (Johnson & Johnson). Market share data is not yet publicly available since it's not yet approved
Market Dynamics
Industry Overview
The pharmaceutical industry, particularly the autoimmune and inflammatory disease segment, is characterized by high growth potential, driven by aging populations and increased prevalence of chronic diseases. It's highly competitive and regulated.
Positioning
Immunic Inc. is a clinical-stage biopharmaceutical company. They aim to develop differentiated oral therapies targeting specific immune pathways, potentially offering advantages over existing treatments in terms of convenience and efficacy. Immunic Inc. positions itself as a novel oral treatment option.
Total Addressable Market (TAM)
The autoimmune disease market is estimated at $150 billion. Immunic Inc. aims to capture a portion of this TAM with its novel oral therapies which are designed to improve current treatment options for inflammatory bowel disease and multiple sclerosis.
Upturn SWOT Analysis
Strengths
- Novel oral therapies in development
- Targeting large and growing markets
- Focused development strategy
Weaknesses
- Clinical-stage company with no approved products
- High cash burn rate
- Reliance on successful clinical trial outcomes
- Dependent on future financing to fund operations
Opportunities
- Positive clinical trial results
- Potential for partnerships with larger pharmaceutical companies
- Expansion into new indications
- FDA approvals
Threats
- Clinical trial failures
- Competition from existing and emerging therapies
- Regulatory hurdles
- Patent expirations
- Market access challenges
Competitors and Market Share
Key Competitors
- Biogen (BIIB)
- Novartis (NVS)
- AbbVie (ABBV)
- Johnson & Johnson (JNJ)
Competitive Landscape
Immunic competes with established pharmaceutical companies with approved therapies for autoimmune diseases. Its advantage lies in its novel oral therapies, which could offer improved convenience and efficacy. However, it faces challenges related to clinical trial success, regulatory approval, and market access.
Growth Trajectory and Initiatives
Historical Growth: Historically, growth has been defined by advancement through clinical trials and fundraising activities.
Future Projections: Future growth is tied to the successful development and commercialization of its drug candidates. Analyst projections vary widely based on clinical trial outcomes.
Recent Initiatives: Recent initiatives include advancing clinical trials for Vidofludimus Calcium and IMU-935, presenting data at scientific conferences, and securing financing.
Summary
Immunic Inc. is a clinical-stage company with promising oral therapies for autoimmune diseases. Success hinges on clinical trial outcomes and regulatory approvals. The company must effectively manage its cash burn and navigate a competitive landscape with established players. They are speculative.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Immunic Inc. Investor Relations
- SEC Filings
- Industry Reports
- Analyst Reports
- Company Press Releases
Disclaimers:
This analysis is based on publicly available information and analyst estimates. It is not financial advice. Investing in biotechnology companies is inherently risky.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Immunic Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2014-04-17 | CEO & Director Dr. Daniel Vitt Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 90 | Website https://imux.com |
Full time employees 90 | Website https://imux.com | ||
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.